PENUMBRA INC (PEN)
Sector: Health Care
2026 Annual Meeting Analysis
PENUMBRA INC · Meeting: June 18, 2026
Directors FOR
2
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Against Analysis
Dr. Bose is classified as non-independent by the board due to his status as a former employee and co-founder, and he serves on no committees, but the policy flags a non-independent director serving alongside the CEO co-founder with a longstanding insider relationship; more critically, the proxy discloses that Adam Elsesser's son Aidan Elsesser is a paid employee of the company, establishing a familial relationship between the CEO/director and a company employee — while that specific flag targets senior management family members, Dr. Bose's non-independent status as a long-tenured insider co-founder tied to the same founding group warrants an AGAINST vote on independence grounds, and the TSR trigger does not apply as PEN outperforms both its peer group median (+37.0pp vs. 35pp threshold) and IHI.
For Analysis
Ms. O'Rourke is independent, has served since April 2017, chairs the Audit Committee, holds CPA credentials qualifying her as an audit financial expert, and PEN's 3-year TSR outperforms the peer group median by +37.0pp, well below the 35pp underperformance threshold needed to trigger an AGAINST vote, so no policy flags apply.
Ms. Sarna is independent, has served since July 2019, brings relevant medical device and life sciences CEO experience, and PEN's strong relative TSR performance versus both the peer group and IHI means no underperformance trigger applies.
Of the three Class II nominees, two (O'Rourke and Sarna) receive a FOR vote — both are independent, qualified, and no TSR or attendance flags apply. Dr. Bose receives an AGAINST vote because he is classified as non-independent due to his insider co-founder status as a former employee; the board's own designation confirms he is not independent, and his long-standing insider ties to the founding management group raise governance concerns that are not offset by any policy mitigant. The TSR trigger does not apply to any nominee as Penumbra outperforms its peer group.
Say on Pay
✓ FORCEO
Adam Elsesser
Total Comp
$851,621
Prior Support
98%%
CEO Adam Elsesser's total 2025 compensation was $851,621 — consisting entirely of base salary ($850,000) and a small benefits amount — which is exceptionally modest for the CEO of a $12.7B market cap medical device company and well below any benchmark threshold that would trigger concern. The compensation program for other named executive officers is structured around base salary plus performance-linked stock awards tied to revenue and operating margin targets, with no cash bonuses, which represents a reasonable pay-for-performance design. Penumbra's stock returned +14.0% over three years versus a -10.0% return for the IHI (iShares US Medical Devices ETF), demonstrating strong pay-for-performance alignment, and the prior year's say-on-pay vote received approximately 98% shareholder support with no material changes needed.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
2 yrs
Audit Fees
$2,518,500
Non-Audit Fees
$2,000
PwC was first engaged for fiscal year 2024 (selected March 2024, replacing Deloitte), giving it approximately two years of tenure — well below the 25-year threshold that would trigger concern. Non-audit fees of $2,000 (a software license) represent less than 0.1% of audit fees of $2,518,500, far below the 50% ratio that would raise independence concerns. PwC is a Big 4 firm appropriate for a $12.7B market cap company, and no restatements or other negative factors are disclosed.
Overall Assessment
The 2026 Penumbra annual meeting ballot contains three proposals: director elections, auditor ratification, and an advisory say-on-pay vote. The overall governance picture is favorable — CEO pay is unusually modest, stock performance has outpaced the medical device sector benchmark IHI, PwC is newly engaged with minimal non-audit fees, and two of the three director nominees are independent and well-qualified — with the sole AGAINST vote going to co-founder Dr. Bose on non-independence grounds.
Compensation Peer Group
20 companies disclosed in 2026 proxy filing